Product Overview
KLOW is a multi-compound formulation supplied by Arche Research containing GHK-Cu, BPC-157, TB-500, and KPV. It is supplied as a lyophilized material in multiple selectable formulations for lawful laboratory, analytical, and non-clinical research.
Included Compounds
- GHK-Cu
- BPC-157
- TB-500
- KPV
Research Context
The KLOW formulation contains four distinct research compounds. The scientific references below are organized by compound to preserve clarity regarding the material examined in each publication.
Research References
GHK-Cu Research References
Pickart L, Margolina A. “Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.” International Journal of Molecular Sciences. 2018;19(5):1303. DOI: 10.3390/ijms19051303. Pickart L. “The human tri-peptide GHK and tissue remodeling.” Wound Repair and Regeneration. 2008;16(6):720-728. DOI: 10.1111/j.1524-475X.2008.00433.x.
BPC-157 Research References
Sikiric P, et al. “Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications.” Journal of Neurogastroenterology and Motility. 2016;22(2):235-242. DOI: 10.5056/jnm16018. Hahm KB, et al. “Benefits of BPC-157 in gastric ulcer healing.” Journal of Physiology and Pharmacology. 2010;61(5):551-558.
TB-500-Related Research References (Note: The following citations examine the full-length 43-amino acid Thymosin Beta-4 protein. Material sold under the “TB-500” designation frequently consists of shorter synthetic fragments, such as the LKKTETQ active site. Therefore, findings related to the full-length protein should not be assumed to be equivalent to all synthetic TB-500 fragment variants.)
Philp D, et al. “Thymosin beta 4 promotes hair growth in normal rats and mice.” Journal of Investigative Dermatology. 2004;123(5):845-851. DOI: 10.1111/j.0022-202X.2004.23426.x. Sosne G, et al. “Thymosin beta 4 promotes corneal wound healing.” Experimental Eye Research. 2001;82(4):597-606. DOI: 10.1016/j.exer.2004.10.004.
KPV Research References
Mason S, et al. “KPV: A Potential Therapeutic Peptide for Inflammatory Bowel Disease.” Clinical and Experimental Gastroenterology. 2020;13:313-321. DOI: 10.2147/CEG.S253588. Ichiyama A, et al. “Inhibition of LPS-induced cytokine release by alpha-melanocyte-stimulating hormone and its C-terminal tripeptide KPV.” Journal of Immunology. 1999;163(6):3329-3334.
